Oric Pharmaceuticals Inc

NASDAQ ORIC

Data sourced from iex and EODHD
Download Data

Oric Pharmaceuticals Inc Income Statement 2019 - 2024

This table shows the Income Statement for Oric Pharmaceuticals Inc going from 2019 until 2024. The income statement, also known as the profit and loss statement, is a financial statement that provides a summary of a company's revenues, expenses, and net income over a specific period (such as a quarter or a year). It shows the company's ability to generate revenue, manage expenses, and ultimately determine its profitability.
Income Statement Trend Unit 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31
Revenue
M 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Cost of Revenue
M 1 1 1 - - - - - - - - - - - - - - - - - -
Gross Profit
M 0 -1 -1 - - - - - - - - - - - - - - - - - -
Operating Expenses
M 115 110 100 - - - - - - - - - - - - - - - - - -
Selling, General, and Administrative Expenses (SG&A)
M 26 26 24 24 25 25 25 25 24 22 20 18 16 13 11 9 7 6 4 2 1
Research and Development (R&D) Expenses
M 88 85 77 69 64 62 62 60 62 57 52 48 40 36 31 28 25 23 16 10 5
Other Operating Expenses
M 0 -1 -1 - - - - - - - - - - - - - - - - - -
Costs and Expenses
M 113 109 100 - - - - - - - - - - - - - - - - - -
Operating Income
M -114 -111 -101 -98 -94 -92 -92 -85 -86 -79 -84 -91 -82 -74 -55 -36 -31 -29 -20 -13 -6
Interest Expense
M 2 2 3 4 5 3 1 1 0 0 0 0 0 0 1 1 2 2 1 1 0
Non-operating Income/Expense
M 12 10 8 6 4 3 -15 -16 -16 -16 -12 -25 -25 -25 -13 0 0 0 0 0 0
EBT
M -102 -101 -93 -93 -90 -89 -91 -85 -85 -79 -84 -91 -81 -74 -54 -35 -30 -27 -19 -12 -6
Income Tax Provision
M 2 -2 -4 -4 -5 -3 -1 -1 0 0 0 0 0 -1 -1 -2 -2 -2 -2 -1 -1
Income after Tax
M -56 -47 -67 -65 -85 -86 -90 -84 -85 -79 -84 -91 -81 -73 -53 -33 -28 -25 -17 -11 -5
Non-Controlling Interest
M 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Net Income
M -23 -47 -68 -93 -90 -89 -91 -85 -85 -79 -84 -91 -81 -74 -45 -26 -21 -19 -19 -12 -6
Shares (Basic, Weighted)
M - - - - - - - - - - - - - - - - - - - - -
Shares (Diluted, Weighted)
R 56,967,506.50 51,402,660.25 47,067,971.50 42,611,330.00 41,068,185.00 39,653,574.00 39,468,794.00 39,326,907.50 38,631,959.50 37,943,950.00 36,502,027.75 34,328,725.25 30,560,106.50 28,275,787.25 24,656,470.25 21,863,046.50 21,241,508.50 19,141,209.00 19,141,209.00 19,141,209.00 19,141,209.00
EBITDA
M -113 -110 -101 -88 -84 -81 -82 -85 -85 -78 -60 -41 -31 -24 -28 -35 -30 -28 -19 -12 -6
Depreciation and Amortization
M 1 1 1 11 11 11 11 1 1 1 1 1 1 1 1 1 1 1 1 0 0
EBIT
M -114 -111 -102 -99 -95 -92 -93 -85 -86 -79 -61 -42 -32 -25 -29 -36 -31 -29 -20 -13 -6
Income from Discontinued Operations
M - - - - - - - - - - - - - - - - - - - - -
Tax Rate (Effective)
% -3.45 4.65 5.13 5.96 4.97 3.01 1.52 0.69 0.22 0.25 0.24 0.21 0.23 1.64 2.86 4.94 6.52 7.43 8.25 8.19 9.84
Earnings Per Share (EPS), Basic
M - - - - - - - - - - - - - - - - - - - - -
Earnings Per Share (EPS), Diluted
M 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Gross Profit Margin
% 82.90 - - - - - - - - - - - - - - - - - - - -
Operating Income Margin
% -2,043.43 - - - - - - - - - - - - - - - - - - - -
Net Income Margin
% - - - - - - - - - - - - - - - - - - - - -
EBITDA Ratio
% -2,026.33 - - - - - - - - - - - - - - - - - - - -
EBIT Ratio
% -2,043.43 - - - - - - - - - - - - - - - - - - - -
EBT Ratio
% -1,842.00 - - - - - - - - - - - - - - - - - - - -

StockViz Staff

September 20, 2024

Any question? Send us an email